 NEW YORK and VIENNA, Austria, Dec. 07, 2020 GLOBE NEWSWIRE -- HOOKIPA Pharma Inc. NASDAQ: HOOK, HOOKIPA, a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced positive interim Phase 1 data on HB-201, its replicating monotherapy for the treatment of HPV16 cancers. The results are from the initial dose escalation cohorts of an ongoing Phase 12 clinical trial NCT04180215 evaluating HB- 201 as therapy for patients with advanced HPV16 metastatic cancers. HOOKIPA will host a conference call and live audio webcast today at 8:30am EST. 